Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help people with HIV and non-alcoholic fatty liver disease by measuring changes in liver fat content.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 51 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-02 · est. completion 2023-09

Where 9 sites · Brazil, United States

What this study is testing ClinicalTrials.gov NCT04216589 ↗

Description as written by the study sponsor.

The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.

Treatments tested

Semaglutide Drug

Administered subcutaneously

Main thing measured	Change (Absolute) in IHTG (%)
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Conditions studied	HIV Infections, Non-Alcoholic Fatty Liver Disease
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04216589 ↗